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SUMMARY Since the beginning of 1999, over 1500 patients with 
symptoms of chronic prostatitis were examined at Dr. Fran Mihaljević 
University Hospital for Infectious Diseases in Zagreb. In almost 
all of these patients urethral swabs and quantitative segmented 
bacteriologic cultures and microscopy of expressed prostatic 
secretion (EPS) or voided bladder urine3 (VB3) were performed 
as described by Meares and Stamey. Urethral swabs, EPS or VB3 
were examined for the presence of Chlamydia (C.) trachomatis by 
McCoy culture and Lugol stain or by immunofluorescent typing with 
monoclonal antibodies. In the majority of patients C. trachomatis was 
demonstrated in parallel in EPS or VB3 by DNA/RNA hybridization 
method. Normal white blood cell count viewed per high power field 
<10 was found in 362 (68%) of 536 patients with symptoms of 
chronic prostatitis and C. trachomatis detected in EPS or VB3. These 
findings additionally suggest that C. trachomatis can be suspected 
as a causative pathogen in all categories of chronic prostatitis 
syndrome. Furthermore, this paper summarizes the results of five 
previously published clinical studies on the efficacy and tolerability 
of various treatment schemes for chronic chlamydial prostatitis, 
conducted from the beginning of 1999 until the end of 2003.
KEY WORDS: Chlamydia trachomatis, prostatitis syndrome, 
diagnosis, treatment
INTRODUCTION
Since the beginning of 1999, as part of three 
scientific research projects of the Ministry of Sci-
ence, Education and Sports of the Republic of 
Croatia (Urogenital infections caused by Chla-
mydia trachomatis, No. 143004; Etiology and 
treatment of chronic prostatitis, No. 0108149; and 
Clinical significance of Ureaplasma urealyticum 
and Mycoplasma hominis, No. 0143003), we have 
been prospectively investigating prostatitis syn-
drome and urogenital infections caused by Chla-
mydia (C.) trachomatis at Outpatient Department 
of Urogenital Infections and Sexually Transmitted 
Diseases, Dr. Fran Mihaljević University Hospital 
for Infectious Diseases, Zagreb.  
Prostatitis syndrome refers to a number of con-
ditions that are presented with urethral symptoms, 
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prostatic symptoms, sexual dysfunction and other 
symptoms like fatigue, myalgia, headache, etc. 
(1). It is diagnosed by clinical symptoms and signs, 
expressed prostatic secretion (EPS) microscopy, 
and culture of EPS and segmented urine samples 
(VB1, VB2, VB3) according to Meares and Stamey 
(2). According to the duration of symptoms, pros-
tatitis is described as acute or chronic when symp-
toms are present for at least 3 months (3).
The classification of prostatitis syndrome ac-
cording to Drach et al. differentiates between:
1) acute bacterial prostatitis (ABP); 
2) chronic bacterial prostatitis (CBP); 
3) nonbacterial prostatitis; and
4) prostatodynia (4).
A new classification of prostatitis syndrome has 
been introduced according to the US National In-
stitutes of Health, 1995:
1) ABP, acute infection of the prostate;
2) CBP, recurrent infection of the prostate; 
3) chronic pelvic pain syndrome (CPPS), no 
demonstrable infection, subdivided into:
(a) inflammatory CPPS, chronic abacterial 
prostatitis, white blood cells in EPS/VB3, and
(b) non-inflammatory CPPS, prostatodynia, no 
white blood cells in EPSs/VB3;
4) asymptomatic inflammatory prostatitis (AIP), 
no subjective symptoms, detected either by pros-
tate biopsy or by the presence of white blood cells 
(WBC) in prostate secretion during evaluation for 
other disorders (5).
C. trachomatis is the most common bacterial 
pathogen of sexually transmitted diseases caus-
ing acute and chronic recurrent but also persistent 
infections. C. trachomatis is a common bacterial 
pathogen causing prostatitis (6,7).
The aim of this paper was to concisely sum-
marize the results of our studies on the diagnosis 
and treatment of chronic prostatitis caused by C. 
trachomatis. 
PATIENTS AND METHODS
 The study was conducted at Outpatient Depart-
ment of Urogenital Infections and Sexually Trans-
mitted Diseases, Dr. Fran Mihaljević University 
Hospital for Infectious Diseases, Zagreb, Croatia 
since March 1, 1999, and is still ongoing. The Hos-
pital Ethics Committee approved the study.
 Patients
 We examined more than 1500 patients older 
than 18 with chronic prostatitis syndrome. The ma-
jority of patients presented to our Outpatient De-
partment for the symptoms of urogenital infection, 
and only some for the symptoms and laboratory 
findings of their sexual partner, reactive arthritis, 
infertility, or for fear from having contracted a sex-
ually transmitted disease. The patients included in 
the study complained of urethral symptoms (irrita-
tive voiding dysfunction, urinary urgency, frequen-
cy, nocturia, dysuria), prostatic symptoms (pain 
and discomfort in the low back and in the perineal, 
suprapubic, penile, scrotal, or groin areas) and 
sexual symptoms (pain during or after ejacula-
tion or erectile dysfunction). In all patients clini-
cal symptoms were present for at least 3 months. 
Ultrasound examination showed no evidence of 
anatomical abnormality of the genitourinary tract 
in these patients.
 Patients with hypersensitivity to macrolides or 
tetracyclines, severe renal or hepatic impairment 
(AST and/or ALT levels twice above the upper lim-
it) as well as patients who had received any oral 
antibiotic 2 weeks prior to study enrolment and 
patients with chronic diarrheal diseases or other 
gastrointestinal conditions that may have affected 
drug absorption, were excluded from the studies 
that investigated the efficacy and tolerability of 
various treatment schemes for the treatment of 
chronic prostate infection caused by C. trachoma-
tis. 
 Diagnostic criteria
The inclusion criteria for C. trachomatis pros-
tatitis were the presence of clinical symptoms of 
chronic prostatitis, presence of C. trachomatis in 
EPS or voided bladder urine collected immedi-
ately after prostatic massage (VB3), absence of 
C. trachomatis in urethral swabs and absence of 
other possible pathogens of chronic prostatitis in 
urethral swab specimens, VB1 (first void urine), 
VB2 (midstream urine), EPS or VB3.
 Methods
The following data were obtained for each 
patient: medical history, clinical status including 
digitorectal prostatic examination, urethral swab 
specimens and selective samples of urine, and 
EPS, according to the 4-glass localization test 
(Meares and Stamey’s localization technique). 
Urethral swab specimens, EPS or VB3 were ex-
amined for the presence of C. trachomatis, Urea-
plasma (U.) urealyticum, Mycoplasma (M.) homi-
nis and Trichomonas (T.) vaginalis. Quantitative 
segmented cultures and bacterial identification in 
three voided samples and EPS were performed 
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at Laboratory of Clinical Microbiology, Dr. Fran 
Mihaljević University Hospital for Infectious Dis-
eases using standard microbiology methods. 
The diagnosis of urogenital mycoplasma was 
confirmed by semiquantitative culturing and anti-
microbial susceptibility test, Mycoplasma duo, and 
S.I.R. Mycoplasma test (Bio-Rad-Laboratories).
The diagnosis of T. vaginalis was confirmed by 
culture on Diamond modified medium (8).
In all patients, the isolation of C. trachoma-
tis was performed at Croatian Institute of Public 
Health, Zagreb, Croatia. From the beginning of 
our study until December 31, 2002, C. trachomatis 
was proved by isolation on McCoy culture and Lu-
gol stain. From January 1, 2003 to date, C. tracho-
matis was proved by isolation on McCoy culture 
and by immunofluorescent typing with monoclonal 
antibodies. In the majority but not all patients, C. 
trachomatis was proved by DNA/RNA Digene hy-
bridization method, which was performed at Labo-
ratory of Molecular Diagnosis, Dr. Fran Mihaljević 
University Hospital for Infectious Diseases.
Clinical efficacy and tolerability of administered 
drug as well as possible adverse events were 
evaluated during, at the end, and at 4-6 weeks of 
therapy completion.
 Clinical response definitions:
cure, complete resolution of urethral, prostatic 
and sexual symptoms;
improvement, incomplete resolution of urethral, 
prostatic or sexual symptoms, but no need for 
additional therapy; and
failure, no apparent response or progression of 
urethral, prostatic or sexual symptoms, or ad-
ditional antibiotic therapy needed.
Bacteriologic efficacy of the administered drug 
was evaluated at 4-6 weeks of therapy completion 
using methods identical to those used on study 
enrolment.
 Bacteriologic response definitions:
eradication, eradication of C. trachomatis at post-
treatment visit; and
persistence, persistence of C. trachomatis at 
post-treatment visit.
 Antimicrobial treatment
Study 1. Azithromycin was administered to 
patients with chronic chlamydial prostatitis, in a 
total dose of 4.5 g for 3 weeks, given as a 3-day 
therapy of 1x500 mg at regular time intervals of 4 
days. The patients’ sexual partners were treated 
at the same time (9).
Study 2. Patients were randomized according 
to a computerized randomization list to receive a 
total dose of 4.5 g of azithromycin given as 3-day 
therapy of 1x500 mg weekly for 3 weeks, or clar-
ithromycin 500 mg b.i.d. for 15 days. The patients’ 
sexual partners were treated at the same time 
(10).
Study 3. Patients were randomized according 
to a computerized randomization list to receive a 
total dose of 4.5 g of azithromycin given as 3-day 
therapy of 1x500 mg weekly for 3 weeks, or cip-
rofloxacin 500 mg b.i.d. for 20 days. The patients’ 
sexual partners were treated at the same time 
(11).
Study 4. Patients were randomized according 
to a computerized randomization list to receive a 
total dose of 4.5 g of azithromycin given as 3-day 
therapy of 1x500 mg weekly for 3 weeks, or a total 
dose of 6.0 g of azithromycin given as 3-day ther-
apy of 1x500 mg for 4 weeks. The patients’ sexual 
partners were treated at the same time (12).
Study 5. Patients were randomized according 
to a computerized randomization list, in a 2/1 ra-
tio, azithromycin/doxycycyline, to receive a total 
dose of 4.0 g of azithromycin given as a single 
1-day therapy of 1x1000 mg weekly for 4 weeks 
or doxycycline 100 mg b.i.d. for 28 days. The pa-
tients’ sexual partners were treated at the same 
time (13).
RESULTS
Through summarized results of our studies, 
already published in various journals, we present 
some of our most relevant findings.
 Etiology of chronic prostatitis (14) – the role 
of unusual pathogens in prostatitis syndrome 
(15)
A total of 1442 patients with symptoms of 
chronic prostatitis were examined during a 4-year 
period at Outpatient Department of Urogenital In-
fections, Dr. Fran Mihaljević University Hospital 
for Infectious Diseases, Zagreb, Croatia. An infec-
tious etiology was determined in 1070 (74.21%) 
patients. Inflammatory finding (>10 WBCs/HPF) 
was detected in EPS or VB3 in 561 (52.4%) of 
these 1070 patients.
Normal finding of <10 WBCs/HPF was record-
ed in 362 (67.54%) of 536 patients with symp-
toms of chronic prostatitis and C. trachomatis, 51 
(33.77%) of 151 patients with T. vaginalis and 40 
(55.56%) of 72 patients with U. urealyticum de-
tected in EPS or VB3. Escherichia (E.) coli was 
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the causative pathogen in 95, Enterococcus in 68, 
Proteus (P.) mirabilis in 37, Klebsiella (K.) pneu-
moniae in 16, Streptococcus (S.) agalactiae in 19, 
and Pseudomonas (P.) aeruginosa in three pa-
tients with chronic prostatitis. Other patients had 
mixed infection. In patients with chronic bacterial 
prostatitis caused by E. coli, P. mirabilis, K. pneu-
moniae, Enterococcus or S. agalactiae, inflam-
matory finding was regularly recorded in EPS or 
VB3.
In all patients, C. trachomatis was detected 
in urethral swab/EPS/VB3 by isolation on McCoy 
culture, until December 31, 2002 by Lugol stain, 
and from January 1, 2003 by immunofluorescent 
typing with monoclonal antibodies. In the majority 
but not all patients, C. trachomatis was proved in 
EPS/VB3 by DNA/RNA Digene hybridization meth-
od. When EPS/VB3 originated from the same sam-
ple, C. trachomatis was detected by two different 
methods, and comparison of the results thus ob-
tained showed that C. trachomatis was three times 
more frequently detected by isolation on McCoy 
culture and using Lugol stain than by DNA/RNA 
hybridization, i.e. as frequently detected by isola-
tion on McCoy culture as by immunofluorescent 
typing with monoclonal antibodies and DNA/RNA 
hybridization.
 Antimicrobial treatment for chronic prosta-
titis caused by C. trachomatis
 Study 1. Azithromycin in the treAtment of chron-
ic prostAtitis cAused by Chlamydia traChomatis (9).
The study included 46 patients older than 18 
with symptoms of chronic prostatitis, inflammatory 
findings, and presence of C. trachomatis in EPS or 
VB3. C. trachomatis was confirmed by isolation on 
McCoy culture and by Lugol stain. Patients were 
treated with a total dose of 4.5 g of azithromycin 
for 3 weeks, given as 3-day therapy of 1x500 mg 
at regular 4-day intervals. Bacterial eradication 
occurred in 40/46 (86.99%) and disappearance of 
symptoms in 30/46 (65.21%) patients.
Study 2. compArAtive AnAlysis of Azithromycin 
And clArithromycin efficAcy And tolerAbility in the 
treAtment of chronic prostAtitis cAused by Chla-
mydia traChomatis (10).
The study included 123 patients older than 18 
with symptoms of chronic prostatitis, inflamma-
tory findings and presence of C. trachomatis con-
firmed by DNA/RNA Digene hybridization in EPS 
or voided urine collected immediately after pros-
tatic massage. The patients were randomized to 
receive a total dose of 4.5 g of azithromycin for 3 
weeks, given as 3-day therapy of 1x500 mg week-
ly or clarithromycin 500 mg b.i.d. for 15 days. In 
the group of patients with chronic chlamydial pros-
tatitis, the eradication rate (azithromycin 37/46 
and clarithromycin 36/45) and clinical cure rate 
(azithromycin 32/46 and clarithromycin 32/45) did 
not differ significantly according to the drug admin-
istered (p>0.05). In the group of patients with as-
ymptomatic chlamydial prostatitis, the eradication 
rate (azithromycin 11/16 and clarithromycin 10/15) 
did not differ significantly according to the drug ad-
ministered (p=1.00; OR=1.1).
Study 3. compArAtive AnAlysis of Azithromycin 
And ciprofloxAcin in the treAtment of chronic pros-
tAtitis cAused by Chlamydia traChomatis (11).
The study included 89 patients aged >18 years 
with symptoms of chronic prostatitis, inflammatory 
findings and presence of C. trachomatis confirmed 
by DNA/RNA Digene hybridization method and/or 
isolation on McCoy culture and Lugol stain in EPS 
or in voided urine collected immediately after pros-
tatic massage. The patients were randomized to 
receive a total dose of 4.5 g of azithromycin for 3 
weeks, given as 3-day therapy of 1x500 mg week-
ly or ciprofloxacin 500 mg b.i.d. for 20 days. A sig-
nificantly higher eradication rate (36/45 vs. 17/44; 
p=0.0002) and clinical cure rate (31/45 vs. 15/44; 
p=0.0021) were achieved in the group of patients 
treated with azithromycin than in the ciprofloxacin 
group.
Study 4. Azithromycin: 4.5- or 6.0-grAm dose in 
the treAtment of pAtients with chronic prostAtitis 
cAused by Chlamydia  traChomatis – A rAndomized 
study (12).
The study included 89 patients older than 18 
diagnosed with chronic chlamydial prostatitis. C. 
trachomatis was confirmed by isolation on McCoy 
culture and by Lugol stain. Patients were treated 
with a total dose of 4.5 g of azithromycin given as 
3-day therapy of 1x500 mg weekly for 3 weeks, or 
a total dose of 6.0 g of azithromycin given as 3-
day therapy of 1x500 mg for 4 weeks. In the group 
of patients with chronic chlamydial prostatitis, the 
clinical cure rate (32/46 vs. 31/43; p=0.97) and 
eradication rate (37/46 vs. 35/43; p=1) did not dif-
fer significantly according to the total dose (4.5 g 
or 6.0 g) of azithromycin administered. 
Study 5. compArAtive rAndomized pilot study of 
Azithromycin And doxycycline efficAcy in the treAt-
ment of prostAte infection cAused by Chlamydia 
traChomatis (13).
The study included 125 adult patients aged 
>18 with symptoms of chronic prostatitis and prov-
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en presence of C. trachomatis. The presence of 
C. trachomatis was confirmed in EPS or in voided 
urine collected immediately after prostatic mas-
sage by DNA/RNA hybridization and/or isolation 
on McCoy culture, and then by immunofluores-
cent typing with monoclonal antibodies. The pa-
tients were randomized at a 2/1 ratio of azithro-
mycin/doxycycline to receive a total dose of 4.0 g 
azithromycin over 4 weeks, given as a single dose 
of 1x1000 mg weekly for 4 weeks or doxycycline 
100 mg b.i.d. for 28 days. In the group of patients 
with chlamydial infection of the prostate, there 
was no significant difference in the eradication 
rate (azithromycin 65/82 vs. doxycycline 33/43; 
p=0.82) and clinical cure rate (azithromycin 56/82 
vs. doxycycline 30/43; p=0.94) according to the 
antimicrobial administered.
DISCUSSION AND CONCLUSION
Considering important biological features of C. 
trachomatis for establishing balance with the host 
and causing latent asymptomatic or oligosymp-
tomatic persistent infections leading to various 
cellular inflammatory responses, C. trachomatis 
can be suspected as a causative pathogen in all 
categories of prostatitis syndrome, regardless of 
classification, as described in the last categoriza-
tion (NIDDK). From March 1, 1999 to the present, 
urethral swabs and quantitative segmented bacte-
riological cultures and microscopy of EPS or VB3 
as described by Meares and Stamey were per-
formed in almost all our patients with symptoms of 
chronic prostatitis. Urethral swabs and EPS or VB3 
of all patients were investigated for the presence 
of C. trachomatis, U. urealyticum, M. hominis and 
T. vaginalis. The results of these studies which 
evaluated 1442 patients with inflammatory as well 
as noninflammatory pelvic pain syndrome showed 
they may have had C. trachomatis in their pros-
tate. In our study, normal WBC/HPF (<10) was 
found in 362 (68%) of 536 patients with symptoms 
of chronic prostatitis and C. trachomatis detected 
in EPS or VB3.
As there is no diagnostic method specific 
enough to be recommended as a method of C. 
trachomatis detection in EPS/VB3, we consider 
our findings, with corresponding results obtained 
by isolation of C. trachomatis in EPS/VB3 by Mc-
Coy culture and by immunofluorescent typing with 
monoclonal antibodies and DNA/RNA hybridiza-
tion, significant and useful for investigation of chla-
mydial infections of the prostate.
Assessment of clinical and bacteriological ef-
ficacy and tolerability of a total dose of 4.0, 4.5 
or 6.0 g of azithromycin for 3 or 4 weeks, cipro-
floxacin 500 mg b.i.d. for 20 days, clarithromycin 
500 mg b.i.d. for 15 days, and doxycycline 100 mg 
b.i.d. for 28 days pointed to the following conclu-
sions:
1. in patients with chlamydial prostatitis and in 
patients with inflammatory or noninflammatory 
chronic pelvic pain syndrome, ciprofloxacin is 
not recommended if C. trachomatis is suspect-
ed; 
2. although clarithromycin has been shown to be 
effective and safe in the treatment of chlamydial 
infection of the prostate, it is not registered for 
the treatment of urogenital infections and can-
not be used in daily routine for the treatment 
of chlamydial prostatitis and other chlamydial 
urogenital infections; and
3. in patients with chlamydial infection of the pros-
tate, the drugs of choice are azithromycin in a 
Table 1. Etiology of chronic prostatitis
Microorganism confirmed in EPS or VB3 Patients
>10 WBC/HPF in EPS No. <10 WBC/HPF in EPS No. Total No. (%)
Chlamydia trachomatis 174 362 536 (37.17)
Trichomonas vaginalis 100 51 151 (10.47)
Ureaplasma urealyticum 32 40 72 (4.99)
Escherichia coli 90 5 95 (6.59)
Enterococcus 52 16 68 (4.72)
Proteus mirabilis 35 2 37 (2.57)
Klebsiella pneumoniae 14 2 16 (1.11)
Streptococcus agalactiae 12 7 19 (1.32)
Pseudomonas aeruginosa 2 1 3 (0.21)
Mixed infection 50 23 73 (5.06)
None 91 281 372 (25.79)
Total 652 770 1442 
(100.00)
EPS= expressed prostatic secretion; VB3= postprostatic massage urine
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total dose of 4.0, 4.5 or 6.0 g given periodically 
for 3 or 4 weeks, or doxycycyline 100 mg b.i.d. 
for 4 weeks.
We are fully aware that the research conduct-
ed so far has its disadvantages and flaws. To our 
opinion, the major disadvantages are that clinical 
symptoms of prostatitis have not been followed 
according to the Chronic Prostatitis Symptom In-
dex (NIH-CPSI) and that clinical and bacteriologi-
cal evaluation of therapeutic efficacy at 6 months 
of treatment completion is lacking (16,17).
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